Priscilla Driscoll-Shempp.

Kereiakes, M.D., Robert W. Yeh, M.D., Priscilla Driscoll-Shempp, M.B.A., Donald E. Cutlip, M.D., P. Gabriel Steg, M.D., Sharon-Lise T. Normand, Ph.D., Eugene Braunwald, M.D., Stephen D. Wiviott, M.D., David J. Cohen, M.D., David R. Holmes, Jr., M.D., Mitchell W. Krucoff, M.D., James Hermiller, M.D., Harold L. Dauerman, M.D., Daniel I. Simon, M.D., David E. Kandzari, M.D., Kirk N. Garratt, M.D., David P. Lee, M.D., Thomas K. Pow, M.D., Peter Ver Lee, M.D., Michael J. Rinaldi, M.D., and Joseph M. Massaro, Ph.D. For the DAPT Study Investigators: Twelve or 30 Weeks of Dual Antiplatelet Therapy after Drug-Eluting Stents..We also tested for an interaction between loss-of-function carrier position and both current smoking position12,13 and enough time to the initial event following the initiation of clopidogrel treatment .14 Zero significant interactions had been observed . Discussion Our results suggest that the efficacy and safety of clopidogrel in comparison with placebo are not altered by CYP2C19 loss-of-function alleles. No factor in the effects of clopidogrel treatment on medical outcomes was observed when sufferers were stratified relating to metabolizer phenotype.